Magnus Medical raised $25 million in Series A financing co-led by JAZZ Venture Partners and Red Tree Venture Capital.
The company also announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its individualized, rapid-acting, non-invasive neurostimulation technology designed to treat major depressive disorder (MDD) in people who have not improved sufficiently from antidepressant medication or other treatments. Read more.
Related Posts
Thriveworks Receives Investment From Wellington Management
Regal Healthcare Capital Partners will remain Thriveworks MSO's largest equity holder.
July 28, 2021
Bezos Family Donates $710M to Fred Hutchinson Cancer Center in Seattle
The donation will fund 36 new research labs, the building of a large research facility, investments in clinical trial infrastructure and immunotherapy research over ten years, the center said.
October 13, 2022
Materna Medical Raises $22M
The femtech sector has steadily risen in the ranks of venture capital funding as more and more startups dedicated to women’s health have sprung up.
August 2, 2022